Pancreatic Cancer Breakthrough: New Daily Pill Doubles Survival Time For Advanced Patients
Published on: June 2, 2026, 11:42 a.m. | Source: NDTV.com
A new once-daily targeted therapy, daraxonrasib, has nearly doubled survival in patients with advanced pancreatic cancer in a landmark Phase 3 trial. Experts are calling it one of the most significant breakthroughs against one of the world's deadliest cancers in decades.
